Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VHEA for AML with KMT2A Gene Abnormalities
NCT06328179Recruiting
- Start
- May 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML). Primary endpoint: Overall Response Rate at 1 year. Started May 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06328179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328179.